NAYA Biosciences, Inc. (NAYA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NAYA Biosciences, Inc. (NAYA) with AI Score 59/100 (Hold). NAYA Biosciences, Inc. operates as a medical device company focused on infertility solutions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026NAYA Biosciences, Inc. (NAYA) Healthcare & Pipeline Overview
NAYA Biosciences, Inc. specializes in medical devices for infertility treatment, primarily through its INVOcell technology, which facilitates in vivo fertilization. With a focus on providing accessible and patient-centered solutions, NAYA operates within the competitive medical device landscape, targeting the growing infertility treatment market.
Investment Thesis
NAYA Biosciences presents a focused investment opportunity within the fertility treatment market. The company's INVOcell technology offers a potential alternative to traditional IVF, appealing to patients seeking less invasive and more cost-effective solutions. With a market capitalization of $0.00 billion, NAYA's growth hinges on increasing adoption of INVOcell by fertility clinics and demonstrating superior outcomes. Key catalysts include expanding regulatory approvals and strategic partnerships to broaden market reach. However, the company faces risks associated with competition from established IVF providers and the need for continuous innovation. The negative P/E ratio of -0.03 and a profit margin of -476.4% highlight the challenges in achieving profitability. The company's beta of 2.04 indicates higher volatility compared to the market. Successful execution of its commercialization strategy and efficient management of operating expenses are critical for NAYA to realize its potential.
Based on FMP financials and quantitative analysis
Key Highlights
- INVOcell is NAYA Biosciences' flagship product, offering an in vivo fertilization system as an alternative to traditional IVF.
- Gross margin of 37.1% indicates the profitability of INVOcell sales before operating expenses.
- The company operates in the reproductive health sector, addressing the growing demand for infertility treatments.
- Market capitalization of $0.00B reflects the company's current valuation in the market.
- Beta of 2.04 suggests higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Innovative INVOcell technology
- Potential cost advantages
- Focus on patient-centered care
- Established relationships with fertility clinics
Weaknesses
- Limited market share compared to established IVF providers
- Dependence on a single product (INVOcell)
- Negative profit margin
- Small company size
Catalysts
- Upcoming: Securing regulatory approvals in new geographic regions to expand market reach.
- Ongoing: Forming strategic partnerships with fertility clinics and medical professionals.
- Ongoing: Investing in research and development to enhance INVOcell technology.
- Ongoing: Launching awareness campaigns to educate patients and medical professionals.
- Ongoing: Demonstrating the cost-effectiveness of INVOcell compared to traditional IVF.
Risks
- Potential: Competition from established IVF providers with greater resources and market share.
- Potential: Technological advancements in IVF that may render INVOcell obsolete.
- Potential: Regulatory changes that may impact the approval and commercialization of INVOcell.
- Ongoing: Economic downturns that may affect patient affordability and demand for infertility treatments.
- Ongoing: Dependence on a single product (INVOcell) for revenue generation.
Growth Opportunities
- Expanding Market Reach: NAYA Biosciences has the opportunity to expand its market reach by securing regulatory approvals in new geographic regions. This includes targeting emerging markets with growing demand for infertility treatments. The global fertility services market is projected to reach $36 billion by 2026, offering a significant opportunity for NAYA to increase its revenue through geographic expansion. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with fertility clinics and medical professionals can accelerate the adoption of INVOcell technology. Collaborating with established players in the reproductive health sector can provide NAYA with access to a wider customer base and enhance its credibility. These partnerships can also facilitate the integration of INVOcell into existing treatment protocols. Timeline: Ongoing.
- Product Development: Investing in research and development to enhance the INVOcell technology and develop new products for infertility diagnosis and treatment can drive long-term growth. This includes exploring new applications for in vivo fertilization and developing complementary products to improve treatment outcomes. Timeline: Ongoing.
- Cost-Effectiveness: Highlighting the cost-effectiveness of INVOcell compared to traditional IVF can attract price-sensitive patients and increase market share. By demonstrating that INVOcell can deliver comparable outcomes at a lower cost, NAYA can position itself as a more accessible option for infertility treatment. Timeline: Ongoing.
- Awareness Campaigns: Launching awareness campaigns to educate patients and medical professionals about the benefits of INVOcell can drive demand and increase adoption. This includes participating in industry conferences, publishing clinical studies, and engaging with patient advocacy groups. Timeline: Ongoing.
Opportunities
- Expanding market reach through regulatory approvals
- Strategic partnerships with fertility clinics
- Developing new products for infertility diagnosis and treatment
- Increasing awareness of INVOcell benefits
Threats
- Competition from established IVF providers
- Technological advancements in IVF
- Regulatory changes
- Economic downturns affecting patient affordability
Competitive Advantages
- Proprietary INVOcell technology
- Potential cost advantages compared to traditional IVF
- Focus on in vivo fertilization
- Established relationships with fertility clinics
About NAYA
NAYA Biosciences, Inc. is a medical device company dedicated to providing innovative solutions for infertility. The company's flagship product, INVOcell, is an in vivo fertilization system that allows for fertilization and early embryo development to occur within the woman's body, offering a more natural and intimate approach to assisted reproductive technology (ART). This technology differentiates itself from traditional in vitro fertilization (IVF) by simplifying the process and potentially reducing costs for patients. Founded with the goal of expanding access to fertility treatments, NAYA Biosciences has focused on developing and commercializing INVOcell as a viable alternative to conventional IVF. The company's business model involves the sale and distribution of INVOcell devices to fertility clinics and medical professionals. NAYA Biosciences operates within the broader medical device industry, specifically targeting the reproductive health sector. The company's success is closely tied to its ability to demonstrate the efficacy and cost-effectiveness of INVOcell compared to traditional IVF, as well as its ability to navigate the regulatory landscape and secure approvals for its technology in various markets. NAYA Biosciences is headquartered in Sarasota, US, and currently employs 30 individuals.
What They Do
- Develops and commercializes medical devices for infertility treatment.
- Offers INVOcell, an in vivo fertilization system.
- Provides a less invasive alternative to traditional IVF.
- Focuses on expanding access to fertility treatments.
- Distributes INVOcell devices to fertility clinics.
- Aims to improve treatment outcomes for infertility patients.
Business Model
- Sells INVOcell devices to fertility clinics and medical professionals.
- Generates revenue through the sale of its flagship product.
- Focuses on expanding market reach through strategic partnerships.
- Invests in research and development to enhance its technology.
Industry Context
NAYA Biosciences operates within the medical device industry, specifically targeting the reproductive health sector. The industry is characterized by increasing demand for infertility treatments, driven by factors such as delayed pregnancies and lifestyle changes. The competitive landscape includes established IVF providers and other medical device companies offering assisted reproductive technologies. NAYA Biosciences aims to differentiate itself through its INVOcell technology, which offers a less invasive and potentially more cost-effective alternative to traditional IVF. The company's success depends on its ability to demonstrate the efficacy and benefits of INVOcell compared to existing solutions and to expand its market reach through strategic partnerships and regulatory approvals.
Key Customers
- Fertility clinics
- Medical professionals specializing in reproductive health
- Infertility patients seeking alternative treatment options
Financials
Chart & Info
NAYA Biosciences, Inc. (NAYA) stock price: Price data unavailable
Latest News
-
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
benzinga · Dec 17, 2024
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NAYA.
Price Targets
Wall Street price target analysis for NAYA.
MoonshotScore
What does this score mean?
The MoonshotScore rates NAYA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Steven M. Shum
CEO
Steven M. Shum serves as the CEO of NAYA Biosciences, Inc. He has experience in managing teams and driving business growth. His background includes leadership roles in various companies, focusing on strategic planning, operational efficiency, and market expansion. He is responsible for overseeing the company's overall strategy, managing its resources, and ensuring its long-term success.
Track Record: Under Steven M. Shum's leadership, NAYA Biosciences has focused on expanding the market reach of INVOcell and establishing strategic partnerships with fertility clinics. He has overseen the company's efforts to secure regulatory approvals in new geographic regions and to increase awareness of the benefits of INVOcell. His focus has been on driving adoption of the technology and improving treatment outcomes for infertility patients.
NAYA Biosciences, Inc. Stock: Key Questions Answered
What does NAYA Biosciences, Inc. do?
NAYA Biosciences, Inc. is a medical device company focused on providing innovative solutions for infertility treatment. Its primary product, INVOcell, is an in vivo fertilization system that allows fertilization and early embryo development to occur within the woman's body. This technology offers a less invasive and potentially more cost-effective alternative to traditional in vitro fertilization (IVF). NAYA Biosciences aims to expand access to fertility treatments and improve outcomes for infertility patients by commercializing and distributing INVOcell to fertility clinics and medical professionals.
What do analysts say about NAYA stock?
AI analysis is currently pending for NAYA Biosciences, Inc. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is not yet available. Once the AI analysis is complete, a neutral summary of analyst perspectives will be provided. This will include information on the company's financial performance, growth prospects, and potential risks, without recommending buying or selling the stock. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for NAYA?
NAYA Biosciences faces several risks, including competition from established IVF providers, technological advancements in IVF that may render INVOcell obsolete, regulatory changes that may impact the approval and commercialization of INVOcell, economic downturns that may affect patient affordability and demand for infertility treatments, and dependence on a single product (INVOcell) for revenue generation. These risks could negatively impact the company's financial performance and growth prospects. Effective risk management and mitigation strategies are crucial for NAYA to achieve its long-term goals.
What are the key factors to evaluate for NAYA?
NAYA Biosciences, Inc. (NAYA) currently holds an AI score of 59/100, indicating moderate score. Key strength: Innovative INVOcell technology. Primary risk to monitor: Potential: Competition from established IVF providers with greater resources and market share.. This is not financial advice.
How frequently does NAYA data refresh on this page?
NAYA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NAYA's recent stock price performance?
Recent price movement in NAYA Biosciences, Inc. (NAYA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative INVOcell technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NAYA overvalued or undervalued right now?
Determining whether NAYA Biosciences, Inc. (NAYA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NAYA?
Before investing in NAYA Biosciences, Inc. (NAYA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- AI analysis is pending and will provide further insights into the company's prospects.